Childhood Epidermolysis Bullosa Acquisita During Squaric Acid Dibutyl Ester Immunotherapy for Alopecia Areata

    December 2016 in “ British Journal of Dermatology ”
    Liliana Guerra, Valeria Pacifico, Valentina Calabresi, Naomi De Luca, Daniele Castiglia, Chiara D’Angelo, Giovanna Zambruno, Giovanni Di Zenzo
    TLDR A 6-year-old boy's skin condition improved after stopping a specific treatment and starting new medications.
    A 6-year-old boy developed the inflammatory variant of epidermolysis bullosa acquisita (EBA) shortly after starting immunotherapy with squaric acid dibutyl ester (SADBE) for scalp alopecia areata. The EBA symptoms rapidly regressed after discontinuing SADBE and initiating combined steroid and dapsone therapy, with no recurrence after treatment tapering and withdrawal. This case suggested a possible role of SADBE in triggering EBA, marking the first reported instance of EBA occurring during alopecia areata treatment.
    Discuss this study in the Community →

    Cited in this study

    1 / 1 results